Suchergebnisse

Within the European Union (EU), documenting the burden of invasive pneumococcal disease (IPD) in infants and children is important for coordinating effective pneumococcal immunization policies. Our objective was to document the burden of IPD in countries of the EU plus Switzerland and Norway. European affiliates of Wyeth Vaccines made available recent epidemiological data on IPD from local disease surveillance programmes, including unpublished sources. Recent literature and websites were also searched to provide as wide a representation as possible. This included OVID and abstracts from a number of international meetings, dating from the year 2000. The reported rates of paediatric IPD per 100 000 (age) ranged from a low of 1·7 (<2 years) to 4·2 (2–15 years) in Sweden to a high of 93·5 to 174 (<2 years) to 56·2 (<5 years) in Spain. The percentage of circulating serotypes causing IPD that are covered by 7-valent pneumococcal conjugate vaccine (PCV) IPD serotype coverage ranged from 60% to 80% for European children aged <2 years. Under reporting, differences in reporting methods, antibiotic prescribing and disparities in blood-culturing practices may explain the differences in reported disease incidence. Because of the excellent clinical efficacy of the PCV against IPD, national pneumococcal vaccination programmes in Europe have the potential to prevent much morbidity and mortality.

Formalised knowledge systems, including universities and research institutes, are important for contemporary societies. They are, however, also arguably failing humanity when their impact is measured against the level of progress being made in stimulating the societal changes needed to address challenges like climate change. In this research we used a novel futures-oriented and participatory approach that asked what future envisioned knowledge systems might need to look like and how we might get there. Findings suggest that envisioned future systems will need to be much more collaborative, open, diverse, egalitarian, and able to work with values and systemic issues. They will also need to go beyond producing knowledge about our world to generating wisdom about how to act within it. To get to envisioned systems we will need to rapidly scale methodological innovations, connect innovators, and creatively accelerate learning about working with intractable challenges. We will also need to create new funding schemes, a global knowledge commons, and challenge deeply held assumptions. To genuinely be a creative force in supporting longevity of human and non-human life on our planet, the shift in knowledge systems will probably need to be at the scale of the enlightenment and speed of the scientific and technological revolution accompanying the second World War. This will require bold and strategic action from governments, scientists, civic society and sustained transformational intent.

Formalised knowledge systems, including universities and research institutes, are important for contemporary societies. They are, however, also arguably failing humanity when their impact is measured against the level of progress being made in stimulating the societal changes needed to address challenges like climate change. In this research we used a novel futures-oriented and participatory approach that asked what future envisioned knowledge systems might need to look like and how we might get there. Findings suggest that envisioned future systems will need to be much more collaborative, open, diverse, egalitarian, and able to work with values and systemic issues. They will also need to go beyond producing knowledge about our world to generating wisdom about how to act within it. To get to envisioned systems we will need to rapidly scale methodological innovations, connect innovators, and creatively accelerate learning about working with intractable challenges. We will also need to create new funding schemes, a global knowledge commons, and challenge deeply held assumptions. To genuinely be a creative force in supporting longevity of human and non-human life on our planet, the shift in knowledge systems will probably need to be at the scale of the enlightenment and speed of the scientific and technological revolution accompanying the second World War. This will require bold and strategic action from governments, scientists, civic society and sustained transformational intent.

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

International audience ; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers). ; Peer reviewed

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.)

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. in its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.) ; Stallergenes ; ALK-Abello ; European Academy of Allergy and Clinical Immunology (EAACI) ; MSD ; Novartis ; Nycomed/Takeda ; PHADIA/Thermo Fischer ; 3M ; AstraZeneca ; GlaxoSmithKline ; Merck Frosst ; Altair ; Amgen ; Asmacure ; Boehringer-Ingelheim ; Genentech ; Pharmaxis ; Schering ; Wyeth ; Ache ; Brazilian Research Council ; Fundacao de Amparo a Pesquisa da Bahia ; Fundacao Ciencia e Tecnologia ; Sociedade Portuguesa de Alergologia e Immunologia Clinica ; Abdi Ibrahim ; OrionPharma ; Nasonebs ; Merck ; McNeal ; Chiesi ; Nycomed ; Air Liquid Healthcare ; Mundipharma ; Almirall ; Kyorin ; Teva ; UK National Health Service ; Aerocrine ; AKL Ltd ; PREDICTA ; Swiss National Science Foundation ; MeDALL ; Global Allergy and Asthma European Network (GA 2LEN) ; Christine Kuthe Center for Allergy Research and Education ; Faes Farma ; Bial ; Johnson Johnson ; Sanofi ; HAD treasurer ; Innovative Medicine Initiative (EU) ; Helse Sor-Ost RHF (Southern and Eastern Norway Regional Health Authority) ; MEDA ; Alcon ; ISTA ; Thermo-Fisher ; Airsonett ; Medical Research Council ; Moulton Charitable Trust ; AB Science ; Canadian Institutes for Health Research ; AllerGen NCE ; Merck/Schering-Plough ; Circassia ; University Hospital ; Medical School of Universidad Autonoma de Nuevo Leon, Mexico ; Children's Research Foundation (Ireland) ; Danone ; Food Standards Agency (United Kingdom) ; European Union (EU) ; DTG ; Netherlands Asthma Foundation ; Merck-Sharp-Dohme, Mexico ; Allerquim Mexico ; Abbott ; Apotex ; HRA ; MedImmune ; Schering-Plough ; Proctor Gamble ; Sunovion (Sepracor) ; Phadia ; Servier ; CSC JohnsonJohnson ; Oxygen Plus ; New Medics ; European Respiratory Society ; Societe de Pneumologie de Langue Francaise Asthma ; Ministry of Health, Welfare, and Labor ; Altana ; Takeda ; UCB ; Uriach advisory board ; NAPP ; Royal College of GPs Clinical Champion in Allergy ; Agency for Healthcare Research and Quality (AHRQ) ; AnseII ; Bayer Schering ; OST ; Fujisawa ; IHAL ; Henkel ; Kryolan ; Leti ; MSO ; Procter and Gamble ; Sanofi-Aventis ; Scientific Advisory Board for the German Society for Allergy and Clinical Immunology ; German Federal Ministry of Consumer Protection ; European Centre for Allergy Research Foundation (ECARF) ; Hop Arnaud Villeneuve, Dept Resp Dis, Univ Hosp, Montpellier, France ; INSERM, U1018, CESP Ctr Res Epidemiol & Populat Hlth, Resp & Environm Epidemiol Team, Villejuif, France ; McMaster Univ, Dept Clin Epidemiol & Biostat & Med, Hamilton, ON, Canada ; Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland ; Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, U657, Montpellier, France ; Catholic Univ, Fac Med, Res Ctr Resp Med CIMER, Cordoba, Argentina ; Univ Genoa, Sch Specializat, Genoa, Italy ; Univ Ghent, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium ; CNR, Inst Translat Pharmacol, Rome, Italy ; Univ Naples 2, Naples, Italy ; Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada ; Univ Genoa, Dept Internal Med, DIMI, I-16126 Genoa, Italy ; Creighton Univ, Dept Med, Div Allergy & Immunol, Omaha, NE 68178 USA ; Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil ; CNPq, Salvador, BA, Brazil ; Univ Amsterdam, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands ; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands ; Univ Porto, Sch Med, Dept Hlth Informat & Decis Sci, P-4100 Oporto, Portugal ; Univ Porto, Sch Med, CINTESIS, P-4100 Oporto, Portugal ; Hosp S Joao & Inst, Dept Allergy, Oporto, Portugal ; Hosp CUF Porto, Oporto, Portugal ; Erasmus MC, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands ; Univ Washington, Sch Med, Seattle, WA USA ; Helsinki Univ Hosp, Dept Allergy, Skin & Allergy Hosp, Helsinki, Finland ; GARD ARIA Coordinator, Geneva, Switzerland ; Med Univ Lodz, Dept Internal Med Asthma & Allergy, Barlicki Univ Hosp, Lodz, Poland ; Univ S Florida, Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL 33612 USA ; James A Haley Vet Hosp, Tampa, FL USA ; Univ Oslo, Oslo Univ Hosp, Dept Paediat, Oslo, Norway ; CIBERES, IDIBAPS, Hosp Clin, Rhinol Unit,ENT Dept, Barcelona, Spain ; CIBERES, IDIBAPS, Hosp Clin, Smell Clin,ENT Dept, Barcelona, Spain ; Univ Chicago, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA ; Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia ; Monash Univ, Melbourne, Vic 3004, Australia ; Teikyo Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo 173, Japan ; EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium ; Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece ; Nippon Med Sch, Bunkyo Ku, Tokyo 113, Japan ; Univ Aberdeen, Dept Primary Care Resp Med, Aberdeen, Scotland ; Woodbrook Med Ctr, Loughborough, Leics, England ; Univ Edinburgh, Edinburgh, Midlothian, Scotland ; Univ Manitoba, Fac Med, Winnipeg, MB, Canada ; NIAID, Bethesda, MD 20892 USA ; Univ N Carolina, Sch Pharm, Chapel Hill, NC USA ; Celal Bayar Univ, Sch Med, Dept Pulmonol, Manisa, Turkey ; Allergy & Asthma Inst, Islamabad, Pakistan ; Med Univ Graz, Dept Dermatol, Graz, Austria ; Showa Univ, Sch Med, Div Allergol & Resp Med, Tokyo 142, Japan ; Transylvania Univ, Fac Med, Brasov, Romania ; Int Union TB & Lung Dis Union, Paris, France ; Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland ; Minist Hlth, Publ Hosp Med Serv, Antananarivo, Madagascar ; INSERM, EPAR U707, Paris, France ; Univ Paris 06, EPAR, UMR S, Paris, France ; Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio Bilbao, Spain ; Univ Cape Town, Dept Med, Fac Hlth Sci, Div Pulmonol, ZA-7925 Cape Town, South Africa ; WHO, Collaborating Ctr Asthma & Rhinitis, Montpellier, France ; Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Modena, Italy ; Ctr Hosp Univ Rabta, Serv Pneumol Allergol, Tunis, Tunisia ; Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands ; Hop Mami, Ariana, Tunisia ; Bangladesh Lung Fdn, Dhaka, Bangladesh ; Natl Inst Dis Chest & Hosp, Dhaka, Bangladesh ; Charite, Dept Dermatol, Allergy Ctr Charite, D-13353 Berlin, Germany ; Univ Med Ctr, Dept Dermatol & Allergy, Bonn, Germany ; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark ; Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark ; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA ; Univ Verona, Dept Paediat, I-37100 Verona, Italy ; Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada ; Hop Malbaie, La Malbaie, PQ, Canada ; Univ Leicester, Inst Lung Hlth, Leicester LE1 7RH, Leics, England ; Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England ; Ctr Med Docente La Trinidad Caracas, Dept Immunol, Caracas, Venezuela ; Univ Austral Chile, Fac Med, Dept Pediat, Valdivia, Chile ; Univ Fed Sao Joao del Rei, Hlth Sci Ctr, Hlth Sci Postgrad Program, Divinopolis, Brazil ; Univ Cartagena, Immunol Res Inst, Cartagena de Indias, Colombia ; So Calif Res, Mission Viejo, CA USA ; Metropolitan Univ Barranquilla, Allergy & Immunol Lab, Barranquilla, Colombia ; IRCCS San Raffaele Pisana, Rome, Italy ; Univ Cattolica Sacro Cuore, Dept Thorac Surg, Rome, Italy ; Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands ; Capital Inst Pediat, Asthma Clin, Natl Cooperat Grp Pediat Res Asthma, Beijing, Peoples R China ; Capital Inst Pediat, Educ Ctr, Beijing, Peoples R China ; Ctr Asthma Res & Educ, Beijing, Peoples R China ; Hop Arnaud Villeneuve, Univ Hosp, Allergy Unit, Montpellier, France ; Univ Hosp, Dept Allergol, Sch Med CEU San Pablo Madrid, Madrid, Spain ; Georgian Natl Univ, AIETI Med Sch, SEU Clin, Med Ctr, Tbilisi, Rep of Georgia ; Univ Genoa, Dept Internal Med, IRCCS Azienda Osped Univ San Martino, I-16126 Genoa, Italy ; Univ Montpellier I, Primary Care Dept, Montpellier, France ; Nova SE Univ, Coll Osteopath Med, Davie, FL USA ; Univ Manchester, Manchester, Lancs, England ; Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark ; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany ; TUM, Div Environm Dermatol, Munich, Germany ; TUM, Allergy Helmholtz Ctr, Munich, Germany ; Univ Hosp Strasbourg, Chest Dis Dept, Div Pulmonol Asthma & Allergol, Strasbourg, France ; Univ Med & Pharm Iuliu Hatieganu, Dept Allergy, Med Clin 3, Romanian Soc Allergy & Clin Immunol, Cluj Napoca, Romania ; McMaster Univ, AllerGen NCE, Dept Med, Hamilton, ON, Canada ; McMaster Univ, AllerGen NCE, Michael G DeGroote Sch Med, Div Clin Immunol & Allergy,Fac Hlth Sci, Hamilton, ON, Canada ; Univ Versailles St Quentin, Hop Foch, UPRES EA 220, Suresnes, France ; Ctr Hosp Reg Annecy, Serv Pneumol, Annecy, France ; Univ Ss Cyril & Methodius, Univ Clin Pulmonol & Allergy, Skopje, Macedonia ; Georgia Hlth Sci Univ, Augusta, GA USA ; Ctr Hosp Univ Beni Messous, Serv Pneumoallergol, Algiers, Algeria ; Vilnius Univ, Fac Med, Collaborating Ctr GA2LEN, Vilnius, Lithuania ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England ; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA ; Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt ; Egyptian Soc Pediat Allergy & Immunol, Cairo, Egypt ; Soc Marocaine Malad Resp, Casablanca, Morocco ; Ctr Resp Dis & Allergy, Casablanca, Morocco ; Vilnius Univ, Fac Med, Vilnius, Lithuania ; Univ Milan, Sch Med, Melloni Hosp, Milan, Italy ; Educ Hlth, Warwick, England ; Dokkyo Med Univ, Mibu, Tochigi, Japan ; WHO, Country Off Georgia, Tbilisi, Rep of Georgia ; Clin Ricardo Palma, Lima, Peru ; Univ Nuevo Leon UANL, Hosp Univ, Fac Med, Monterrey, Mexico ; Ctr Allergy & Immunol, Tbilisi, Rep of Georgia ; Clin Hosp Univ Chile, Dept Med, Immunol & Allergol Div, Santiago, Chile ; Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium ; Cent Reg Denmark, Ctr Publ Hlth & Qual Improvement, Aarhus, Denmark ; Allergy Ctr Vienna W, Vienna, Austria ; Natl Univ Ireland Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland ; Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England ; Univ Paris 11, Serv Pneumol, Hop Antoine Beclere, AP HP,INSERM,U999, Clamart, France ; Salvador Univ, Sch Med, Dept Immunol, Buenos Aires, DF, Argentina ; Univ St Andrews, St Andrews, Fife, Scotland ; Univ Paris, APHP, Ctr Asthme & Allergies, Grp Hosp Trousseau La Roche Guyon, F-75252 Paris, France ; Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, Ankara, Turkey ; George Washington Univ, Sch Med, Washington, DC USA ; Inst Asthma & Allergy, Chevy Chase, MD USA ; Hacettepe Univ Hosp, Dept Chest Dis, Adult Allergy Unit, Ankara, Turkey ; Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany ; McMaster Univ, Hamilton, ON, Canada ; Hotel Dieu France, Serv Pneumol & Reanimat Med, Beirut, Lebanon ; Univ St Joseph, Fac Med, Beirut, Lebanon ; Natl Med Ctr, Seoul, South Korea ; Seoul Natl Univ, Seoul, South Korea ; Korea Asthma Allergy Fdn, Seoul, South Korea ; Ctr Hosp Univ, Serv Malad Resp, Abidjan, Cote Ivoire ; Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Beatrix Childrens Hosp,Dept Pediat Pulmonol & Ped, Groningen, Netherlands ; Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland ; Karolinska Inst, Dept Clin Sci & Educ, Stockholm, Sweden ; Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden ; Vilnius Univ, Ctr Pulmonol & Allergol, Vilnius, Lithuania ; Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania ; Hosp Med Sur, Dept Allergy, Mexico City, DF, Mexico ; Univ Med & Pharm, Thanh Pho Ho Chi Minh, Vietnam ; Hop Sacre Coeur Montreal, Montreal, PQ, Canada ; Univ Montreal, Montreal, PQ, Canada ; Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China ; Univ Tennessee, Coll Med, Memphis, TN USA ; Univ Dundee, Ninewells Hosp, Asthma & Allergy Res Grp, Dundee, Scotland ; Dubai Hlth Author, Sharjah, U Arab Emirates ; Univ Sharjah, Sharjah, U Arab Emirates ; Univ Mississippi, Med Ctr, Div Clin Immunol & Allergy, Jackson, MS 39216 USA ; Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA ; Univ Arizona, Inst BIO5, Tucson, AZ USA ; Shahid Beheshti Univ Med Sci, NRITLD, Tehran, Iran ; Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, Tehran, Iran ; Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany ; Maputo Cent Hosp, Dept Peadiat, Maputo, Mozambique ; Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique ; Childrens Hosp La Fe, Unit Pediat Allergy & Pneumol, Valencia, Spain ; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden ; Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden ; Univ Calif San Diego, Allergy & Asthma Med Grp, San Diego, CA 92103 USA ; Univ Calif San Diego, Res Ctr, San Diego, CA 92103 USA ; IMSS, Dept Allergy & Clin Immunol, Ctr Med Nacl Siglo 21, Mexico City, DF, Mexico ; Univ Aachen, Dept Dermatol, Aachen, Germany ; Inst Pneumol Marius Nasta, Bucharest, Romania ; Tishreen Univ, Sch Med, Dept Internal Med, WHO EMRO Collaborating Ctr Training & Res Chron R, Latakia, Syria ; CUF Descobertas Hosp, Immunoallergy Dept, Lisbon, Portugal ; Univ Padua, Dept Pediat, Food Allergy Referral Ctr Veneto Reg, Padua, Italy ; Mustapha Hosp, Algiers, Algeria ; Sci Ctr Childrens Hlth RAMS, Moscow, Russia ; Hosp Hospitaller Bros Buda, Budapest, Hungary ; Charite, Allergie Ctr Charite ECARF, Dept Dermatol Venerol & Allergy, D-13353 Berlin, Germany ; German Red Cross Hosp Westend, Berlin, Germany ; Jagiellonian Univ, Sch Med, Dept Pulmonol, Krakow, Poland ; Kinshasa Univ, ENT Dept, Kinshasa, Zaire ; Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan ; Nippon Med Sch, Dept Otolaryngol, Bunkyo Ku, Tokyo 113, Japan ; Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso ; Marmara Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey ; Mem Hlth Grp, Istanbul, Turkey ; Charles Univ Prague, Fac Med Plzen, Dept Immunol & Allergol, Prague, Czech Republic ; MESSERLI Res Inst, Vienna, Austria ; Med Univ Vienna, Univ Vet Med Vienna, Vienna, Austria ; Univ Vienna, Vienna, Austria ; Ajou Univ, Sch Med, Suwon 441749, South Korea ; NICE, Paris, France ; Soc Pneumol Langue Francaise, Paris, France ; Krankenhaus Hietzing, Karl Landsteiner Inst Expt & Clin Pneumol, Dept Pulm Med, Vienna, Austria ; Alexanders Univ Hosp, Clin Allergy & Asthma, Sofia, Bulgaria ; Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pulmonol, Groningen, Netherlands ; Univ Cape Town, Lung Inst, ZA-7925 Cape Town, South Africa ; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa ; Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands ; Grosshansdorf Clin, Grosshansdorf, Germany ; Hop Prive Athis Mons, Serv Pneumol, Athis Mons, France ; Helsinki Univ Hosp, Dept Dermatol, Skin & Allergy Hosp, Helsinki, Finland ; Tech Univ Munich, CKCARE, Dept Dermatol Allergy Biederstein, Munich, Germany ; Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA ; Med Univ Silesia, Dept & Clin Internal Dis Allergol & Clin Immunol, Katowice, Poland ; Complesso Integrato Columbus, Allergy Unit, Rome, Italy ; IRCCS Oasi Maria SS, Troina, Italy ; Son Pisa Primary Care Ctr, IB Salut Balear Hlth Serv, Int Primary Care Resp Grp, Palma de Mallorca, Spain ; Hosp Luz, Immunoallergy Dept, Lisbon, Portugal ; Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA ; Childrens Mercy Hosp, Kansas City, MO USA ; Emek Med Ctr, Afula, Israel ; Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel ; Ctr Med Docente La Trinidad, Dept Allergy & Clin Immunol, Caracas, Venezuela ; UCL, Royal Natl TNE Hosp, London, England ; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland ; Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland ; Universidade Federal de São Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, São Paulo, Brazil ; Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan ; Ctr ACI Immunoflow, Czech Initiat Asthma, Prague, Czech Republic ; GAAPP, Vienna, Austria ; Ctr Res Environm Epidemiol CREAL, Barcelona, Spain ; Pontificia Univ Catolica RGS, Sch Med, Porto Alegre, RS, Brazil ; Univ Nevada, Sch Med, Reno, NV 89557 USA ; Hosp Mar, Municipal Inst Med Res IMIM, Barcelona, Spain ; CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain ; Univ Pompeu Fabra UPF, Barcelona, Spain ; Jagiellonian Univ, Coll Med, Krakow, Poland ; Coimbra Univ Hosp, Immunoallergy Dept, Coimbra, Portugal ; Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA ; Finnish Inst Occupat Hlth, Helsinki, Finland ; Univ Laval, Fac Med, Dept Obstet & Gynecol, Laval, PQ, Canada ; Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria ; Hosp Clin Barcelona, Dept Pneumol, Allergy Unit, Immunoallergia Resp Clin, Barcelona, Spain ; IDIBAPS, Barcelona, Spain ; CIBERES, Barcelona, Spain ; Univ Paris 13, Bobigny, France ; Avicenne Hosp, AP HP, Bobigny, France ; Vilnius Univ, Fac Med, Dept Paediat, Vilnius, Lithuania ; Lithuanian Natl Council Childs Hlth, Vilnius, Lithuania ; Terveystalo Turku, Allergy Clin, Turku, Finland ; Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland ; Univ Ghent, Dept Otorhinolaryngol, B-9000 Ghent, Belgium ; Catholic Univ Louvain, Univ Hosp Mt Godinne, Yvoir, Belgium ; Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands ; Siriraj Hosp, Fac Med, Dept Pediat, Bangkok, Thailand ; CNR, IBIM, Palermo, Italy ; Clin Physiol IFC, Pisa, Italy ; Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore ; Floridsdorf Allergy Ctr FAZ, Vienna, Austria ; Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria ; Bradford Teaching Hosp Fdn Trust, Bradford Inst Hlth Res, Bradford, W Yorkshire, England ; Olmsted Med Ctr, Dept Res, Rochester, MN USA ; Univ Minnesota, Dept Family & Community Hlth, Rochester, MN USA ; Harvard Univ, Sch Publ Hlth, Cyprus Int Inst Environm & Publ Hlth Assoc, Limassol, Cyprus ; Cyprus Univ Technol, Limassol, Cyprus ; Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, ZA-7925 Cape Town, South Africa ; Catholic Univ Cordoba, Sch Med, Dept Otorhinolaryngol, Cordoba, Argentina ; Guangzhou Med Univ, Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China ; Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China ; Univ Clin Resp & Allerg Dis, Golnik, Slovenia ; Charite, Network Excellence, Global Allergy & Asthma European Network GA2LEN, D-13353 Berlin, Germany ; Universidade Federal de São Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, São Paulo, Brazil ; Web of Science

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease. ; European Innovation Partnership ; Montpellier Univ Hosp, Montpellier, France ; European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif France, MACVIA France, Montpellier, France ; INSERM, Ageing & Chron Dis Epidemiol & Publ Hlth Approach, U1168, F-94800 Villejuif, France ; Katholieke Univ Leuven, Dept Microbiol & Immunol, Clin Immunol Lab, Louvain, Belgium ; Transylvania Univ Brasov, Brasov, Romania ; Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium ; Charite, Dept Dermatol & Allergy, Allergy Ctr Charite, Berlin, Germany ; Global Allergy & Asthma European Network, Berlin, Germany ; iQ4U Consultants Ltd, London, England ; Odense Univ Hosp, Dept Dermatol, Odense, Denmark ; Odense Univ Hosp, Allergy Ctr, Odense, Denmark ; Univ Sydney & Sydney Local Hlth Dist, Woolcock Inst Med Res, Glebe, NSW, Australia ; Hosp City Hlth & Sci Torino, Univ Pneumol Unit AOU Molinette, Turin, Italy ; Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France ; Univ Fed Minas Gerais, Dept Pediat, Sch Med, Belo Horizonte, MG, Brazil ; Humanitas Univ, Asthma & Allergy Clin, Milan, Italy ; Univ S Florida, Div Allergy Immunol, Tampa, FL USA ; Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands ; Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil ; GARD Execut Comm, Salvador, BA, Brazil ; EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium ; INSERM, EPAR U707, Paris, France ; Univ Paris 06, EPAR UMR S UPMC, Paris, France ; Suresnes Univ Versailles, Hop Foch, Lab Pharmacol Resp UPRES EA220, St Quentin en Yvelines, France ; Univ Porto, Ctr Res Hlth Technol & Informat Syst CINTESIS, Oporto, Portugal ; Inst CUF Porto, Allergy Unit, Oporto, Portugal ; Hosp CUF Porto, Oporto, Portugal ; Univ Porto, Fac Med, Hlth Informat & Decis Sci Dept CIDES, Rua Dr Placido da Costa S-N, P-4200450 Oporto, Portugal ; Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands ; Erasmus Univ, Inst Hlth Policy & Management IBMG, Rotterdam, Netherlands ; Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland ; Univ Naples Federico II, Hosp Naples R&D & DISMET, Naples, Italy ; Univ Paris 06, UPMC,Equipe EPAR, Sorbonne Univ,Dept Allergol,Inst Pierre Louis Epi, Hopital Enfants Armand Trousseau,AP HP,Ctr Asthme, F-75013 Paris, France ; Charite, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany ; Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany ; Ctr Rhinol & Allergol, Wiesbaden, Germany ; Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland ; Univ Barcelona, CIBERES, IDIBAPS, Hosp Clin,ENT Dept,Clin & Expt Resp Immunoallergy, M Barcelona, Catalonia, Spain ; Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA ; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA ; Monash Univ, Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia ; Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia ; Monash Univ, Dept Immunol, Melbourne, Vic, Australia ; Univ Manchester, Royal Manchester Childrens Hosp, Inst Human Dev, Ctr Pediat & Child Hlth, Manchester, Lancs, England ; Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Pediat Clin 2, Dept Allergy, Athens, Greece ; Nippon Med Sch, Dept Pediat, Tokyo, Japan ; Univ Cape Town, Lung Inst, Allergy Diagnost & Clin Res Unit, Cape Town, South Africa ; Woodbrook Med Ctr, Loughborough, Leics, England ; Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland ; Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland ; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada ; Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland ; Univ Manitoba, Fac Med, Dept Immunol, Dept Pediat & Child Hlth, Winnipeg, MB, Canada ; Univ Salerno, Div Allergy & Clin Immunol, Salerno, Italy ; Univ Coimbra, Fac Med, Ctr Pneumol, Coimbra, Portugal ; Med Univ Graz, Dept ENT, Graz, Austria ; Vilnius Univ, Fac Med, Clin Childrens Dis, Vilnius, Lithuania ; Vilnius Univ, Inst Publ Hlth, Vilnius, Lithuania ; European Acad Paediat EAP UEMS SP, Brussels, Belgium ; Univ Turku, Dept Lung Dis & Clin Allergol, Turku, Finland ; Terveystalo, Allergy Clin, Turku, Finland ; Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Bari, Italy ; Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden ; Karolinska Inst, Inst Environm Med, Stockholm, Sweden ; Queens Univ, Belfast, Antrim, North Ireland ; Celal Bayar Univ, Dept Pulmonol, Manisa, Turkey ; Med Univ Graz, Dept Dermatol, Graz, Austria ; Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland ; Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain ; Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain ; IMIM Hosp Mar Res Inst, Barcelona, Spain ; CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain ; Univ Pompeu Fabra, Barcelona, Spain ; Kyomed, Montpellier, France ; Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden ; Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Dept Pediat Pulmonol & Allergy, Stockholm, Sweden ; David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England ; Reg Puglia, Bari, Italy ; Portuguese Natl Programme Resp Dis PNDR, Fac Med Lisbon, Lisbon, Portugal ; Univ Palermo, Dept Internal Med DIBIMIS, Geriatr Unit, Palermo, Italy ; Univ Cape Town, Dept Med, Cape Town, South Africa ; Univ Modena & Reggio Emilia, Dept Oncol Haematol & Resp Dis, Sect Resp Dis, Modena, Italy ; Univ Amsterdam, Acad Med Ctr, Dept Resp Med, Amsterdam, Netherlands ; Natl Inst Dis Chest & Hosp, Dept Resp Med, Dhaka, Bangladesh ; Linkoping Univ, Fac Med, Dept Pediat, Ctr Individualized Med, S-58185 Linkoping, Sweden ; Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany ; Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden ; Montpellier Univ Hosp, Dept Geriatr, BLAIN Montpellier, France ; Univ Montpellier, Euromov, EA 2991, Montpellier, France ; Univ Milan, IRCCS Fdn CaGranda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Milan, Italy ; Univ Verona Hosp, Dept Pediat, Verona, Italy ; Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, Rome, Italy ; Univ Naples 2, Naples, Italy ; Italian Natl Res Council, Inst Translat Med, Naples, Italy ; Univ Laval, Quebec Heart & Lung Inst, Quebec City, PQ, Canada ; Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland ; Univ Hosp Leicester NHS Trust, Inst Lung Hlth, Resp Biomed Unit, Leicester, Leics, England ; Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England ; Johannes Gutenberg Univ Mainz, Univ Med, Mainz, Germany ; Univ Med & Farm Timisoara, Timisoara, Romania ; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp NHS, London, England ; Ctr Med Docente Trinidad, Caracas, Venezuela ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England ; Reg Languedoc Roussillon, Montpellier, France ; Hosp Valle De Hebron, S Allergol S Med Interna, Barcelona, Spain ; CEDOC, Resp Res Grp, Nova Med Sch, Lisbon, Portugal ; Ctr Hosp Lisboa Cent, EPE, Serv Imunoalergol, Lisbon, Portugal ; Reg Minist Hlth Andalusia, Seville, Spain ; Oslo Univ Hosp, Dept Paediat, Oslo, Norway ; Univ Oslo, Oslo, Norway ; Allergy & Asthma Associates Southern Calif, Mission Viejo, CA USA ; Metropolitan Univ, Univ Simon Bolivar, Allergy & Immunol Lab, Barranquilla, Colombia ; SLaai Sociedad Latinoamer Allergia Asma & Immunol, Cartagena, Colombia ; Gerontopole Toulouse, F-31059 Toulouse, France ; Univ Crete, Fac Med, Dept Social Med, Iraklion, NE, Greece ; Univ CEU San Pablo, Sch Med, Madrid, Spain ; Grigol Robakidze Univ, David Tvildiani Med Univ, AIETI Med Sch, Chachava Clin, Tbilisi, Rep of Georgia ; Pulmonolory Res Inst FMBA, Moscow, Russia ; GARD Execut Comm, Moscow, Russia ; IRCCS Azienda Osped Univ San Martino, Dept Med, Genoa, Italy ; Univ Minho, Sch Hlth Sci, Res Inst ICVS, ICVS 3BsPT Govt Associate Lab,Life & Hlth Sci, Braga, Portugal ; Nova Southeastern Univ, Dept Med, Davie, FL USA ; Scottish Ctr Telehealth & Telecare, NHS 24, European Innovat Partnership Act & Hlth Ageing, Reference Site,EIP AHA, Glasgow, Lanark, Scotland ; Univ London Imperial Coll Sci Technol & Med, Dept Pediat, London, England ; Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden ; Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany ; Helmholtz Ctr Munich, ZAUM Ctr Allergy & Environm, Munich, Germany ; AQuAS, Barcelona, Spain ; European Reg & Local Hlth Assoc, EUREGHA, Brussels, Belgium ; Luliu Hatieganu Univ Med & Pharm, Allergol & Immunol Discipline, Cluj Napoca, Romania ; McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON, Canada ; Peercode DV, Amsterdam, Netherlands ; Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France ; Univ Paris 05, Hop Cochin, AP HP, Serv Physiol Resp, Paris, France ; Ss Cyril & Methodius Univ, Fac Med, Univ Clin Pulmol & Allergy, Skopje, Macedonia ; Ctr Hosp Univ Beni Messous, Serv Pneumoallergol, Algiers, Algeria ; Ecole Mines, Ales, France ; Vilnius Univ, Fac Med, Vilnius, Lithuania ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England ; Kings Coll London, Guys & St Thomas NHS Trust, London, England ; St Louis Univ, Sch Med, Sect Allergy & Immunol, St Louis, MO USA ; Umea Univ, Dept Comp Sci, Umea, Sweden ; Four Comp Oy, Halikko, Finland ; Ain Shams Univ, Pediat Allergy & Immunol Unit, Cairo, Egypt ; Social Serv & Publ Safety, Dept Hlth, Belfast, Antrim, North Ireland ; Global Allergy & Asthma Platform, Altgasse 8-10, A-1130 Vienna, Austria ; Bambino Gesu Childrens Res Hosp Holy See, Dept Pediat Med, Div Allergy, Rome, Italy ; Educ Hlth, Warwick, England ; Reg Hlth Serv Lazio Reg, Dept Epidemiol, Rome, Italy ; Athens Chest Hosp, Athens, Greece ; Natl Ctr Dis Control & Publ Hlth Georgia, Tbilisi, Rep of Georgia ; Istanbul Univ, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey ; Clin Ricardo Palma, Allergy & Immunol Div, Lima, Peru ; Erasmus MC, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands ; Univ Autonoma Nuevo Leon, San Nicolas De Los Garza, Mexico ; Latvian Assoc Allergists, Ctr TB & Lung Dis, Riga, Latvia ; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA ; Univ Hosp Olomouc, Natl eHlth Ctr, Olomouc, Czech Republic ; Univ Chile, Clin Hosp, Immunol & Allergy Div, Santiago, Chile ; Odense Univ Hosp, Dept Resp Dis, Odense, Denmark ; German Res Ctr Environm Hlth, Inst Epidemiol 1, Helmholtz Zentrum Munchen, Neuherberg, Germany ; Vienna Challenge Chamber, Vienna, Austria ; Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland ; Univ Paris 11, Le Kremlin Bicetre, France ; Hop Bicetre, Serv Pneumol, Le Kremlin Bicetre, France ; INSERM, UMR S999, Le Kremlin Bicetre, France ; Univ Plymouth, Sch Psychol, Plymouth, Devon, England ; Univ Salerno, Dept Med & Surg, Baronissi, Italy ; Libra Fdn, Buenos Aires, DF, Argentina ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England ; MRC & Asthma UK Ctr Allerg Mech Asthma, London, England ; Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium ; Montpellier Univ Hosp, Med Commiss, Montpellier, France ; Hallym Univ, Coll Med, Hallym Univ Sacred Heart Hosp, Anyang, Gyeonggi Do, South Korea ; Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland ; Ukrainian Med Stomatol Acad, Poltava, Ukraine ; Fed Medicobiol Agcy, Inst Immunol, Natl Res Ctr, Lab Mol Immunol, Moscow, Russia ; Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, Ankara, Turkey ; Hacettepe Univ, Sch Med, Dept Chest Dis, Immunol & Allergy Div, Ankara, Turkey ; Med Univ Lodz, Dept Family Med 1, Lodz, Poland ; McMaster Univ, Dept Med, Hlth Sci Ctr 3V47, 1280 Main St W, Hamilton, ON, Canada ; Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands ; GARD, Geneva, Switzerland ; Univ Hosp Olomouc, Fac Med & Dent, Dept Resp Med, Olomouc, Czech Republic ; Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Beatrix Childrens Hosp,Dept Pediat Pulmonol & Ped, Groningen, Netherlands ; Med Univ Lodz, Deptment Immunol Rheumatol & Allergy & HARC, Lodz, Poland ; Univ Helsinki, Childrens Hosp, Helsinki, Finland ; Vilnius Univ, Clin Infect Chest Dis Dermatol & Allergol, Vilnius, Lithuania ; Univ Ghent, VIB Inflammat Res Ctr, Ghent, Belgium ; Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany ; Univ Med & Pharm, Hochiminh City, Vietnam ; Univ Tennessee, Coll Med, Dept Internal Med & Pediat, Div Allergy & Immunol, Germantown, TN USA ; Univ Dundee, Ninewells Hosp, Med Res Inst, Scottish Ctr Resp Res Cardiovasc & Diabet Med, Dundee, Scotland ; Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China ; Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway ; CHU Sart Tilman, Dept Pulm Med, Liege, Belgium ; Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria ; Univ Edinburgh, Queens Med Res Inst, Edinburgh, Midlothian, Scotland ; Hop St Joseph, Serv Pneumoallergol, Paris, France ; Univ Nantes, UMR INSERM, Serv Pneumol, UMR1087, Nantes, France ; Univ Nantes, Inst Thorax, CNR 6291, Nantes, France ; Rashid Hosp, Dept Pulm Med, Dubai, U Arab Emirates ; Biomax Informat AG, Munich, Germany ; Univ Bratislava, Dept Resp Med, Bratislava, Slovakia ; Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci, Coimbra, Portugal ; Ageing@Coimbra EIP AHA Reference Site, Coimbra, Portugal ; Bon Secours Hosp, Dept Med, Dublin, Ireland ; Kronikgune, Basque Region, Spain ; Univ Mississippi, Med Ctr, Div Clin Immunol & Allergy, Lab Behav Immunol Res, Jackson, MS USA ; Iranian Anti Tobacco Assoc, Tobacco Control Res Ctr, Tehran, Iran ; Maputo Cent Hosp, Dept Paediat, Maputo, Mozambique ; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA ; Univ Montpellier, Dept Physiol, CHRU, PhyMedExp,INSERM U1046,CNRS UMR 9214, Montpellier, France ; Rhein Westfal TH Aachen, Univ Klinikum, Hautklin Klin Dermatol & Allergol, Aachen, Germany ; Croatian Pulm Soc, Zagreb, Croatia ; Natl Inst Pneumol M Nasta, Bucharest, Romania ; Univ Belgrade, Fac Med, Belgrade, Serbia ; Serbian Assoc Asthma & COPD, Belgrade, Serbia ; Caisse Assurance Retraite & Sante Travail Langued, Montpellier, France ; Tishreen Univ, Sch Med, Natl Ctr Res Chron Resp Dis, Latakia, Syria ; Paris Descartes Univ, Sorbonne Paris Cite, Dept Publ Hlth & Hlth Prod, EA 4064, Paris, France ; Paris Municipal Dept Social Act Childhood & Hlth, Paris, France ; Univ Cologne, Fac Med, Inst Med Stat Informat & Epidemiol, Cologne, Germany ; Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy ; Russian Acad Med Sci, Sci Ctr Childrens Hlth, Moscow, Russia ; Hosp Ninos Orlando Alassia, Santa Fe, Argentina ; Hosp Hosp Bros Buda, Budapest, Hungary ; Hosp La Fe, Neumol & Alergol Infantil, Valencia, Spain ; Ctr Hosp Sao Joao, Dept Internal Med, Oporto, Portugal ; Univ Hosp Kinshasa, ENT Dept, Kinshasa, DEM REP CONGO ; Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan ; Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan ; Nippon Med Sch, Dept Otolaryngol, Tokyo, Japan ; Ctr Hosp Univ Pediatr Charles Gaulle, Ouagadougou, Burkina Faso ; Univ Hosp Pisa, Cardiothorac & Vasc Dept, Pisa, Italy ; Med Univ, Univ Vet Med, Messerli Res Inst, Dept Comparat Med, Vienna, Austria ; Charles Univ Prague, Fac Med, Dept Immunol & Allergol, Plzen, Czech Republic ; Charles Univ Prague, Fac Hosp Pilsen, Plzen, Czech Republic ; Univ Ferrara, Dept Med Sci, Resp Med, Ferrara, Italy ; Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon, South Korea ; Univ Southern Denmark, Kolding, Denmark ; CUF Porto Hosp & Inst, Allergy Unit, Oporto, Portugal ; Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany ; Minist Econ Ind & Numer, Conseil Gen Econ, Paris, France ; Espace Francophone Pneumol, Soc Pneumol Langue Francaise, Paris, France ; CHU Grenoble, Dept Pediat, Grenoble, France ; Childrens Hosp Srebrnjak, Zagreb, Croatia ; Univ JJ Strossmayer, Sch Med, Osijek, Croatia ; Hietzing Hosp, Karl Landsteiner Inst Clin & Expt Pneumol, Vienna, Austria ; Med Univ Sofia, Clin Allergy & Asthma, Sofia, Bulgaria ; Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands ; Copenhagen Univ Hosp Gentofte, Allergy Clin, Lab Med Allergol, Copenhagen, Denmark ; Univ Aberdeen, Acad Ctr Primary Care, Aberdeen, Scotland ; Res Real Life, Cambridge, England ; German Ctr Lung Res DZL, Airway Res Ctr North, LungenClin Grosshansdorf, Grosshansdorf, Germany ; Univ Kiel, German Ctr Lung Res DZL, Airway Res Ctr North, Dept Med, Kiel, Germany ; Southampton Univ Hosp, NHS Fdn Trust, Southampton, Hants, England ; Coimbra Univ Hosp, Ctr Pneumol, Coimbra, Portugal ; Univ Valencia, Polibienestar Res Inst, Valencia, Spain ; Getafe Univ Hosp, Dept Geriatr, Madrid, Spain ; Assoc Asthme & Allergie, Paris, France ; Inst Invest Sanitaria Palma IdisPa, Primary Care Resp Res Unit, Palma De Mallorca, Spain ; Complesso Integrato Columbus, Allergy Unit, Rome, Italy ; Hosp Luz, Serv Imunoalergol, Lisbon, Portugal ; Univ Parana, Hosp Clin, Curitiba, Parana, Brazil ; Emek Med Ctr, Div Allergy Asthma & Clin Immunol, Afula, Israel ; Ctr Med Docente Trinidad & Clin El Avila, Allergy & Clin Immunol Dept, Caracas, Venezuela ; Autononous Univ Madrid, Fac Med, Madrid, Spain ; UCL, Royal Natl TNE Hosp, London, England ; Univ Palermo, DIBIMIS, Palermo, Italy ; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland ; CHU Rangueil Larrey, Otolaryngol & Head & Neck Surg, Toulouse, France ; Queens Univ, Child Hlth, Belfast, Antrim, North Ireland ; Royal Belfast Hosp Sick Children, Belfast, Antrim, North Ireland ; Univ Joseph Fourier, Team Environm Epidemiol Appl Reprod & Resp Hlth, Univ Grenoble Alpes, INSERM,IAB U 1209, Grenoble, France ; Soc Paraguaya Alergia Asma & Inmunol, Asuncion, Paraguay ; Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands ; Univ Fed Sao Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil ; Euro Asian Resp Soc, Kyrgyzstan Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan ; Univ Sao Paulo, Fac Med, Hosp Clin, Div Pulm,Inst Heart InCor, Sao Paulo, Brazil ; Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands ; European Union Geriatr Med Soc EUGMS, Helsinki, Finland ; Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands ; IDIBAPS, Hosp Clin, Pneumol & Allergy Dept, Clin & Expt Resp Immunoallergy, Barcelona, Spain ; PELyon, Lyon, France ; Univ Claude Bernard Lyon, Hlth Serv & Performance Res, HESPER 7425, Villeurbanne, France ; Univ Hosp, Stockholm, Sweden ; Catholic Univ Louvain, Univ UCL Namur, Ctr Hosp Univ UCL Namur, Dept Chest Med, Yvoir, Belgium ; Philippines Soc Allergy Asthma & Immunol, Manila, Philippines ; Res Hosp, Arcispedale S Maria Nuova IRCCS, Dept Cardiol Thorac & Vasc Med, Pulm Unit, Reggio Emilia, Italy ; Reg Agcy Hlth & Social Care, Reggio Emilia, Italy ; Finnish Lung Assoc FILHA, Helsinki, Finland ; CNR Inst Clin Physiol, Pulm Environm Epidemiol Unit, Pisa, Italy ; CNR, Inst Biomed & Mol Immunol A Monroy, Palermo, Italy ; Sotiria Hosp, Athens, Greece ; Univ Klinikum Dusseldorf, HNO Klin, Dept Otorhinolaryngol, Dusseldorf, Germany ; Asthma UK, Mansell St, London, England ; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore, Singapore ; Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Hannover, Germany ; Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA ; IPCRG, Aberdeen, Scotland ; Bradford Royal Infirm, Bradford Inst Hlth Res, Bradford, W Yorkshire, England ; Olmsted Med Ctr, Dept Res, Rochester, MN USA ; Univ Cyprus, Sch Med, Nicosia, Cyprus ; Allergy & Asthma Inst, Lahore, Pakistan ; Univ Southampton, Social Sci, Southampton, Hants, England ; Univ Cape Town, Red Cross Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa ; Univ Cape Town, MRC Unit Child & Adolescent Hlth, Cape Town, South Africa ; Univ Catolica Cordoba, Cordoba, Argentina ; Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China ; Beijing Inst Otolaryngol, Beijing, Peoples R China ; Univ Clin Resp & Allerg Dis, Golnik, Slovenia ; Northern Hlth Alliance, Newcastle Upon Tyne, Tyne & Wear, England ; CHRU Arnaud Villeneuve, 371 Ave Doyen Gaston Giraud, Montpellier 5, France ; Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil ; Web of Science

United States National Science Foundation (NSF) ; Science and Technology Facilities Council (STFC) of the United Kingdom ; Max-Planck-Society (MPS) ; State of Niedersachsen/Germany ; Italian Istituto Nazionale di Fisica Nucleare (INFN) ; French Centre National de la Recherche Scientifique (CNRS) ; Australian Research Council ; International Science Linkages program of the Commonwealth of Australia ; Council of Scientific and Industrial Research of India ; Department of Science and Technology, India ; Science & Engineering Research Board (SERB), India ; Ministry of Human Resource Development, India ; Spanish Ministerio de Economia y Competitividad ; Conselleria d'Economia i Competitivitat and Conselleria d'Educaci, Cultura i Universitats of the Govern de les Illes Balears ; Netherlands Organisation for Scientific Research ; National Science Centre of Poland ; European Union ; Royal Society ; Scottish Funding Council ; Scottish Universities Physics Alliance ; National Aeronautics and Space Administration ; Hungarian Scientific Research Fund (OTKA) ; Lyon Institute of Origins (LIO) ; National Research Foundation of Korea ; Industry Canada ; Province of Ontario through the Ministry of Economic Development and Innovation ; Natural Science and Engineering Research Council, Canada ; Brazilian Ministry of Science, Technology, and Innovation ; Carnegie Trust ; Leverhulme Trust ; David and Lucile Packard Foundation ; Research Corporation ; Alfred P. Sloan Foundation ; NSF ; STFC ; MPS ; INFN ; CNRS ; Science and Technology Facilities Council ; Science and Technology Facilities Council: ST/L000938/1 Gravitational Waves ; Science and Technology Facilities Council: 1362895 ; Science and Technology Facilities Council: ST/L000962/1 ; Science and Technology Facilities Council: ST/I006285/1 Gravitational Waves ; Science and Technology Facilities Council: ST/L003465/1 ; Science and Technology Facilities Council: ST/L000962/1 Gravitational Waves ; Science and Technology Facilities Council: ST/I006285/1 ; Science and Technology Facilities Council: ST/I006242/1 Gravitational Waves ; Science and Technology Facilities Council: ST/J000019/1 ; Science and Technology Facilities Council: ST/N00003X/1 ; Science and Technology Facilities Council: ST/L000946/1 ; Science and Technology Facilities Council: ST/N000064/1 ; Science and Technology Facilities Council: ST/L000954/1 Gravitational Waves ; Science and Technology Facilities Council: ST/K000845/1 ; Science and Technology Facilities Council: ST/I006269/1 ; Science and Technology Facilities Council: ST/L000938/1 ; Science and Technology Facilities Council: Gravitational Waves ; Science and Technology Facilities Council: ST/K005014/1 ; Science and Technology Facilities Council: ST/I006269/1 Gravitational Waves ; We present the results of a search for long-duration gravitational wave transients in two sets of data collected by the LIGO Hanford and LIGO Livingston detectors between November 5, 2005 and September 30, 2007, and July 7, 2009 and October 20, 2010, with a total observational time of 283.0 days and 132.9 days, respectively. The search targets gravitational wave transients of duration 10-500 s in a frequency band of 40-1000 Hz, with minimal assumptions about the signal waveform, polarization, source direction, or time of occurrence. All candidate triggers were consistent with the expected background; as a result we set 90% confidence upper limits on the rate of long-duration gravitational wave transients for different types of gravitational wave signals. For signals from black hole accretion disk instabilities, we set upper limits on the source rate density between 3.4 x 10(-5) and 9.4 x 10(-4) Mpc(-3) yr(-1) at 90% confidence. These are the first results from an all-sky search for unmodeled long-duration transient gravitational waves.

Advanced LIGO ; Science and Technology Facilities Council (STFC) of the United Kingdom ; Australian Research Council ; Council of Scientific and Industrial Research of India, Department of Science and Technology, India ; Science & Engineering Research Board (SERB), India ; Ministry of Human Resource Development, India ; Spanish Ministerio de Economia y Competitividad ; Conselleria d'Economia i Competitivitat and Conselleria d'Educacio, Cultura i Universitats of the Govern de les Illes Balears ; National Science Centre of Poland ; FOCUS Programme of Foundation for Polish Science ; European Union ; Royal Society ; Scottish Funding Council ; Scottish Universities Physics Alliance ; Lyon Institute of Origins (LIO) ; National Research Foundation of Korea ; Industry Canada ; Province of Ontario through the Ministry of Economic Development and Innovation ; National Science and Engineering Research Council Canada ; Brazilian Ministry of Science, Technology, and Innovation ; Research Corporation, Ministry of Science and Technology (MOST), Taiwan ; Kavli Foundation ; Science and Technology Facilities Council ; Science and Technology Facilities Council: ST/L000954/1 Gravitational Waves ; Science and Technology Facilities Council: ST/L000946/1 ; Science and Technology Facilities Council: ST/I006269/1 Gravitational Waves ; Science and Technology Facilities Council: ST/I006242/1 Gravitational Waves ; Science and Technology Facilities Council: ST/L003465/1 ; Science and Technology Facilities Council: ST/J000019/1 ; Science and Technology Facilities Council: ST/N000072/1 ; Science and Technology Facilities Council: ST/K000845/1 ; Science and Technology Facilities Council: ST/I006269/1 ; Science and Technology Facilities Council: ST/N000633/1 ; Science and Technology Facilities Council: ST/M000931/1 ; Science and Technology Facilities Council: ST/K005014/1 ; Science and Technology Facilities Council: PPA/G/S/2002/00652 ; Science and Technology Facilities Council: Gravitational Waves ; Science and Technology Facilities Council: ST/N00003X/1 ; We present a possible observing scenario for the Advanced LIGO and Advanced Virgo gravitational-wave detectors over the next decade, with the intention of providing information to the astronomy community to facilitate planning for multi-messenger astronomy with gravitational waves. We determine the expected sensitivity of the network to transient gravitational-wave signals, and study the capability of the network to determine the sky location of the source. We report our findings for gravitational-wave transients, with particular focus on gravitational-wave signals from the inspiral of binary neutron-star systems, which are considered the most promising for multi-messenger astronomy. The ability to localize the sources of the detected signals depends on the geographical distribution of the detectors and their relative sensitivity, and 90% credible regions can be as large as thousands of square degrees when only two sensitive detectors are operational. Determining the sky position of a significant fraction of detected signals to areas of 5 deg(2) to 20 deg(2) will require at least three detectors of sensitivity within a factor of similar to 2 of each other and with a broad frequency bandwidth. Should the third LIGO detector be relocated to India as expected, a significant fraction of gravitational-wave signals will be localized to a few square degrees by gravitational-wave observations alone.